文献速递痛风与晶体性关节病

美国风湿病学会痛风电子临床质量指标的制定

Development of the American College of Rheumatology Electronic Clinical Quality Measures for Gout.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2018-04-12

美国风湿病学会基于2012年痛风指南开发并测试痛风电子临床质量指标(eCQMs)。10项候选指标中4项获质量措施小组委员会认可,3项纳入RISE登记库,2项获国家质量论坛认可。纳入RISE的3项指标(评估降尿酸治疗指征、监测血尿酸、达标治疗结局)显示高有效性和可靠性,通过率在32%至58%之间。

要点

  • 基于2012年ACR痛风指南开发了10项候选痛风电子临床质量指标。
  • 3项指标纳入RISE登记库:评估降尿酸治疗指征、监测血尿酸、达标治疗结局,显示高有效性和可靠性。
  • RISE和3个测试站点中通过这3项指标的患者比例在32%至58%之间,表明痛风管理有显著改进空间。

核心结论

  • 3项电子临床质量指标已验证并纳入RISE登记库。
  • 其中2项指标(评估降尿酸治疗指征和监测血尿酸)可用于联邦质量报告项目。
  • 这些指标的表现表明痛风管理有显著改进空间。

研究设计与样本

  • 依据2012年ACR痛风指南,工作组开发候选痛风流程指标,经多学科卫生保健利益相关者小组、ACR质量措施小组委员会(QMS)及ACR董事会进行正式有效性测试。
  • 对选定的每项痛风电子临床质量指标,3个使用不同电子健康记录系统的临床站点测试其科学可行性和有效性。
  • 适合问责的指标被提交国家认可。

主要发现

  • 10项候选电子临床质量指标中,4项获ACR QMS认可,3项纳入ACR风湿病学有效性信息学系统(RISE)登记库,2项获国家质量论坛认可。
  • 纳入RISE的3项指标(评估降尿酸治疗指征、监测血尿酸、达标治疗结局)显示高有效性和可靠性。
  • RISE和3个临床测试站点中通过这3项指标的患者比例在32%至58%之间。

关键数值与推荐

  • 10项候选电子临床质量指标中4项获ACR QMS认可。
  • 3项指标纳入RISE登记库。
  • 2项指标获国家质量论坛认可。
  • 通过3项RISE指标的患者比例在32%至58%之间。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Electronic clinical quality measures (eCQMs) are increasingly used by health registries and third parties to evaluate and improve the quality of health care. To complete these eCQMs, data are extracted from electronic health records (EHRs). The treatment of gout has been an area identified with gaps in quality of care. On behalf of the American College of Rheumatology (ACR), we sought to develop and test eCQMs to evaluate gout care. METHODS: Drawing from the 2012 ACR gout guidelines, a working group developed candidate gout process measures that were evaluated by an interdisciplinary panel of health care stakeholders, the ACR Quality Measures Subcommittee (QMS), and ultimately the ACR Board of Directors for formal validity testing. For each of the selected gout eCQMs, 3 clinical sites using different EHR systems tested the scientific feasibility and validity of the measures. Measures appropriate for accountability were presented for national endorsement. RESULTS: Of the 10 proposed eCQMs, 4 were endorsed by the ACR QMS, 3 were incorporated into the ACR's Rheumatology Informatics System for Effectiveness (RISE) Registry, and 2 were endorsed by the National Quality Forum. The 3 eCQMs incorporated into RISE (evaluating indications for urate-lowering therapy [ULT]), monitoring serum urate, and treat-to-target outcome) demonstrated high validity and reliability. Proportions of patients passing these 3 eCQMs in RISE and at the 3 clinical testing sites ranged between 32% and 58%, indicating significant room for improvement in care. CONCLUSION: Three eCQMs have been validated and implemented into RISE. Two of these measures (evaluating indications for ULT and monitoring serum urate) are available for use in federal quality reporting programs. Performance on these measures suggests there is significant room for improvement in the management of gout.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. FitzGerald JD, Mikuls TR, Neogi T, et al. Development of the American College of Rheumatology Electronic Clinical Quality Measures for Gout. Arthritis Care Res (Hoboken). 2018. PMID: 29649348. doi:10.1002/acr.23500

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。